Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives
Table 2
Phase III studies with tiotropium Respimat in children and adolescents with asthma.
Study name
Patients (asthma severity and age)
Treatment duration (weeks)
Baseline therapy
N (treatment group)
Study drug
RubaTinA-asthma
Moderate persistent 12- to 17-year-olds
48
At least ICSs
259
Tiotropium Respimat 2.5 and 5 µg
PensieTinA-asthma
Severe persistent 12- to 17-year-olds
12
ICSs + ≥1 controller
257
CanoTinA-asthma
Moderate persistent 6- to 11-year-olds
48
At least ICSs
270
VivaTinA-asthma
Severe persistent 6- to 11-year-olds
12
At least ICSs/+ ≥1 controller
262
NinoTinA-asthma
Persistent 1- to 5-year-olds
At least ICSs
67
ICSs, inhaled corticosteroids; LABA, long-acting β2-agonist. Table reproduced from E. R. McIvor and R. A. McIvor [20], under the Creative Commons Attribution License/public domain.
